News
08-11-2010, 11:00 PM
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
More... (http://www.news-medical.net/news/20100812/Syndax-raises-246-million-to-support-ENCORE-301-study-in-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20100812/Syndax-raises-246-million-to-support-ENCORE-301-study-in-breast-cancer.aspx)